At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 16 enrolled
Drug / intervention
Crenolanib +6 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study of Crenolanib Combined With Standard Salvage Chmetherapy in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
In Brief
A Phase 2 clinical trial evaluating Crenolanib, Mitoxantrone, and 5 other interventions for Relapsed/Refractory Acute Myeloid Leukemia (AML). Completed, enrolled 16 participants across 4 sites.
Detailed Summary
The proposed study is designed to combine crenolanib with standard salvage chemotherapy to treat patients with R/R AML irrespective the FLT3 status.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 2015
Enrollment StartFeb 2016
Primary CompletionFeb 2018
TodayJul 2026
First PostedDec 10, 2015
Enrollment StartFeb 1, 2016
Primary CompletionFeb 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 10.6 years ago
Interventions
Crenolanibdrug
Mitoxantronedrug
Cytarabinedrug
Etoposidedrug
Fludarabinedrug
G-CSFdrug
Idarubicindrug